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Abstract
Introduction—Children with inherited bleeding disorders often require central venous catheters
(CVC). Although CVCs are known to be complicated by deep venous thrombosis (DVT), little is
known about the timeline of DVT development or risk of post-thrombotic syndrome (PTS).
Aim—To determine the timeline and confirm the incidence of thrombosis in patients with
bleeding disorders who have CVCs.
Methods—In 2002 we instituted a screening program to monitor for CVC-related complications
in children with hemophilia and von Willebrand disease. This is a retrospective review of this
cohort. All children with CVC followed between January 1, 2000 and June 1, 2009 were evaluated
for DVT every 24 months with contrast venography and Doppler sonography. An institutional
PTS severity scale was utilized at each visit.
Results—Thirty-six patients had 37 CVCs placed. Thirty patients had imaging studies, with
DVT observed in 14 (47%). Most DVT were diagnosed at the first venogram (median CVC
duration 26 months). There were no abnormal ultrasound results. Sixteen patients (44%) had
clinical findings consistent with PTS, including 10 (71%) with an abnormal venogram. Dilated
chest wall veins appeared to be more strongly associated with underlying DVT (positive predictive
value of 0.8) than arm circumference discrepancy. Successful transition to use of peripheral veins
occurred at a median of 11 months after abnormal venograms.
Conclusions—CVC-related DVT is common in children with inherited bleeding disorders, and
likely occurs earlier than previously thought. Clinical signs of PTS are also common, but long-
term sequelae and severity of PTS are not known.
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Introduction
Patients with inherited bleeding disorders often require frequent venous access for infusion
of coagulation factors for prophylaxis, immune tolerance induction (ITI), or on demand
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therapy.[1] While peripheral vein infusion is preferred, it is sometimes not feasible in
younger patients. Thus children often require surgically inserted catheters (e.g. Port-a
Cath®, Bard Access Systems, Salt Lake City) to facilitate treatment.[2] Unfortunately, these
devices are associated with infection, mechanical failure and thrombosis.[3] In 2001, we
reported a thrombosis rate of 50% in hemophilia patients utilizing screening contrast
venography. These deep vein thrombi (DVT) were most commonly identified ≥ 48 months
following insertion.[4] Similar results were reported by others.[5, 6] The challenge with
central venous catheter (CVC)-thrombosis has been lack of clarity about the long-term
implications of thrombosis in patients with bleeding disorders and the associated late effects,
particularly post-thrombotic syndrome (PTS). In 2002, we began screening our patients for
thrombotic complications and their sequelae.
The main objective of this study was to determine the timeline of development and confirm
the incidence of CVC-thrombosis in patients with inherited bleeding disorders. Secondary
objectives were 1) to determine if transition to peripheral veins infusion could be
accomplished within 12 months of diagnosis of DVT and/or within 5 years after CVC
insertion and 2) to evaluate for PTS.
Materials and Methods
All children with congenital bleeding disorders who had an indwelling CVC and were
followed at Children’s Medical Center between January 1, 2000 and June 1, 2009 were
included in this retrospective cohort. The following information was collected: type of
bleeding disorder, date of CVC insertion, anatomical location of the CVC, CVC-related
complications, results of imaging studies, PTS evaluation, and the date of CVC removal. We
also documented time to transition to peripheral veins. The duration of CVC insertion was
calculated from date of insertion until date of CVC removal, date of transfer from our center,
or July 1, 2009 for children whose CVC remained in place.
This study was approved by the Institutional Review Board of the University of Texas
Southwestern Medical Center at Dallas.
Education of Patients and Families
The parents of children with bleeding disorders were informed that CVCs were designed to
be in place only temporarily. Since previous studies have demonstrated thrombosis risk ≥ 48
months following insertion, our standard of care is to remove the lines by 5 years after
insertion.[4, 5] If thrombosis was identified, earlier transition to peripheral veins was
attempted within 1 year. Children were managed using the institutional protocol. [7]
Radiographic Screening for CVC-related DVT
Screening imaging for evidence of CVC-related DVT was performed every two years.
Venograms were performed by injection of contrast in the antecubital vein ipsilateral to the
CVC. [8] Bilateral antecubital injections were not performed because families were reluctant
to have two peripheral intravenous lines. In 2004, the jugular vein became the preferred site
for catheter insertion for our surgeons. Doppler ultrasonography, which is more sensitive for
jugular vein DVT, and contrast venography were used to screen after 2004 [7].
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Definition of thrombosis or vascular occlusion identified by screening imaging included: (1)
thrombus in the superior vena cava and/or the subclavian, jugular, brachiocephalic veins; (2)
stenosis; (3) post-stenotic dilation; and/or (4) multiple prominent collateral veins.
Evaluation for Post-thrombotic Syndrome
Families were questioned about CVC complications. Our PTS scale, modified from a
published pediatric tool by Kuhle et al, included evaluation of arm pain, dilated chest wall
veins, and arm circumference discrepancy. [9] Arm circumference was determined using a
paper measuring tape with bilateral arm circumference measured from the same distance
from the antecubital fossa. We utilized the percentage arm circumference difference
calculated as the absolute difference divided by the average of the two arm measurements.
Results were considered abnormal if >2%. [10]
Statistical Analysis
Descriptive analysis was used where appropriate. The incidence rate of thrombosis at 24 and
approximately 5 years after CVC insertion was calculated. Wilcoxan-Mann-Whitney two-
tailed test was used to determine the significance of age, catheter duration, and location
between the patients with positive and negative imaging studies. We conducted analyses
using SAS software, version 9.2 (SAS Institute Inc, Cary, NC). The sensitivity and
specificity of physical examination findings corresponding to catheter-related thrombosis
and PTS were also calculated.
Results
Patients
Thirty-six patients had 37 CVCs inserted. Table 1 describes the study population. One child
with factor VIII deficiency and an inhibitor had two catheters placed. The majority of
children had CVC inserted for prophylaxis (n=30, 83%). The median age at CVC insertion
was 25 months (range 3 – 189 months).
Catheters
All but 5 catheters were inserted at Children’s Medical Center. The catheters were placed in
the subclavian, external jugular, internal jugular, or facial vein. Placement could not be
verified in one patient since the CVC was inserted at another institution and he has not had
imaging performed. All patients had a single lumen Port-A-Cath®. Five patients have
transferred out of our program with their CVC still in place.
Results of Imaging Tests
An initial venogram was performed on 30 patients at a median time of 26 months (range 21–
38 months) after CVC insertion. No patients had complications with venography. Of the 6
patients (with total of 7 catheters) who did not have imaging, 3 had their CVC in place for ≤
25 months, 1 CVC was removed without imaging, 1 transferred to another program, 1
transferred to our center with a line in place >24 months, and one had his CVC removed
because of an infected hematoma. Eight patients had a second venogram performed at
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approximately 4 years after CVC insertion, and 3 boys underwent a third procedure at
approximately 6 years.
DVT was observed in 14 of the 30 (47%) patients. (Figure 1) The incidence of DVT on the
first venogram was 37% (n= 11). The median time of the first abnormal venogram was 26
months after CVC insertion (range 24–82 months). Three additional patients were diagnosed
with DVT after the third image (54, 58, and 82 months respectively). Nine patients had
collateral vessel formation and 4 patients had stenosis. There was no statistical difference in
number of DVT based on location of CVC placement (p=0.5). DVT was identified in 13
patients on prophylaxis, and in 1 on ITI, p= 0.2. (Table 2)
Of the 21 patients with CVCs placed in the jugular or facial veins, 11 also had normal
Doppler ultrasound examinations performed. The other 10 patients did not have sonography
because their CVCs had been in place ≤ 24 months (n=5), they transferred to another
program (n=1), or they had venogram screening performed before routine ultrasonography
was instituted (n=4).
Post-Thrombotic Syndrome
Sixteen of the 36 children with CVCs (44%) had clinical findings consistent with PTS. [9]
These patients had dilated chest wall veins and/or significant ipsilateral arm circumference
difference. Of patients with arm circumference difference, the median was 2.8% (range 2–
9%). All lacked complaints of arm pain or dysfunction unrelated to joint disease. PTS exam
findings were noted at a median time of 27 months post-CVC insertion, and they were
identified in children with and without abnormal venogram results. Ten patients with an
abnormal venogram (71%) had PTS findings. PTS findings did not prompt earlier
venography. Table 3 illustrates the post-thrombotic exam findings. The presence of dilated
chest wall veins had a specificity of 0.94 and a positive predictive value for DVT of 0.8.
Larger ipsilateral arm circumference was less predictive with a sensitivity of 0.6 and a
specificity of 0.7 for DVT.
Outcome of Central Venous Catheters
Twenty-two patients (61%) have had their CVCs removed. Indications for removal included
thrombosis (n=9), peripheral vein transition (n=7), and other complications (n=6). One
patient required replacement due to hardware exposure and another required revision due to
malfunction. The CVC was removed in one patient whose catheter embolized to the
pulmonary artery. Three patients had CVC removal due to infection.
The overall rate of CVC-related infection was 0.059 episodes per 1000 catheter days. The
infectious complications included an infected hematoma, bacteremia, and fatal
staphylococcal sepsis. [11] None of these patients had radiographic evidence of DVT.
Ten (71%) of fourteen patients with a positive venogram had a CVC removed within 12
months after evidence of DVT (median time of 11 months). Delay in removal of CVC was
secondary to parental resistance and/or difficult peripheral venous access (n=2) or transfer to
other programs (n= 2).
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In 2001, we reported a 50% prevalence of thrombosis in children with hemophilia. [4]
However, the time at which this risk and its associated complications are greatest is not
known. Since implementing our screening program, we have identified that up to a third of
patients will develop CVC thrombosis within the first 2 years. However, no one suffered
from pulmonary embolism or arm pain that required anticoagulation treatment.
The screening program also provided a cohort of patients with bleeding disorders and CVC
thrombosis that can be followed prospectively for PTS. PTS is a known complication of
deep vein thrombosis. [9, 12] However, the prevalence and long-term outcome in childhood,
particularly in upper extremities, is not well-defined. Over two-thirds of our patients with
DVT also had signs or symptoms of PTS; however, they need longer follow-up to
understand the long-term implications of DVT and degree of severity of PTS in bleeding
disorder patients.
We determined that 44% of the entire cohort had exam findings consistent with mild PTS.
Abnormal arm circumference measurements were noted in 14 of our patients including 8 of
the 14 (57%) patients with DVT. The findings were accentuated when the CVC was also on
the dominant hand side. It was hypothesized that the increased ipsilateral size was due to
either thrombosis or relative catheter size to the vein size. [13] In our current study, 6
patients without DVT also had a significant arm circumference differences. Therefore, we
questioned if patients can develop symptoms of PTS in the absence of a DVT. We
hypothesize that these children may have had transient catheter-related thrombosis after the
insertion.
The arm circumference measurements in our patients were not performed by a single
practitioner, but rather several in the clinical setting. This, admittedly, complicates
interpretation of the results since there could be measurement error. Additionally, arm
circumference measurements may not be the most reliable indicator of DVT. Furthermore,
PTS evaluations were not performed prior to CVC insertion; therefore, baseline exam
findings were not available for comparison. More patients with CVCs in the chest and arm
veins need to be followed prospectively to determine how much arm circumference
difference will correlate with more severe PTS.
Since 80% of patients with dilated chest wall veins had positive venograms, the presence of
dilated chest wall veins may be more reliable in determining which patients are at higher
risk of having DVT. Patients exhibiting this clinical finding may require screening earlier
than 24 and 48 months. However, due to our small sample size, more patients should be
evaluated to determine if the predictive value of dilated chest wall veins for DVT is upheld.
This is the first study to describe the utility of a CVC screening program and to
prospectively determine the incidence of CVC-related DVT. In addition, it is the first to
assess the prevalence of PTS in children with bleeding disorders and CVCs. Our primary
goal of the screening program was to ensure that patients with bleeding disorders are
transitioned to peripheral veins within 5 years and this has occurred in all but 2 eligible
patients. We wanted to remove catheters earlier if there were any signs of DVT. We were
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able to use peripheral veins within 12 months in 50% of the patients with DVT. For earlier
transition to peripheral veins, we found that it may be necessary to demonstrate thrombosis
on imaging to encourage the transition. Overall, we believe our screening program has been
successful.
It is important to carefully consider which children require CVCs. The ones who do need to
utilize these devices should be monitored closely for CVC complications and the families
need to understand the importance of removing the CVCs as soon as PV infusion becomes
feasible. . Finally, since mild PTS can be seen within a couple of years of CVC removal,
long-term observation of the children diagnosed with DVT is necessary in order to
determine if they develop more severe symptoms of the syndrome.
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Venogram in a 7 year old male with severe Factor VII deficiency with a left subclavian
CVC placed for factor prophylaxis. The venogram demonstrates left axillary vein occlusion
and marked collaterals.
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Number of Patients 36 14 (39%) 16 (44%)
Bleeding Disorder
 Factor VIII Deficiency 28 (78%) 10 (71%) 12 (75%)
 Factor IX Deficiency 6 (17%) 3 (21%) 3 (19%)
 VWD 2 (6%) 1(7%) 1 (6%)
Reason for CVC placement
 Prophylaxis 30 (82%) 13(93%) 13 (81%)
 ITI 7 (19%) 1 (7%) 3 (19%)
Location
 Subclavian 15 (42%) 6 (43%) 7 (44%)
 External Jugular 17 (47%) 8 (57%) 7 (44%)
 Internal Jugular 3 (8%) 0 0
 Facial 1 (3%) 0 1 (6%)
 Not known 1 (3%) 0 1 (6%)
Median Age at CVC placement 33.5
(months) 25 17.5 [21, 51.5]
[25%, 75%] [13, 38] [12, 27] (p= 0.02)
Median CVC duration (months) 52
[25%, 75%] 46 61 [38, 60]
[31, 64] [45, 67] (p= 0.5)
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Table 3





Dilated Chest Wall Veins only 2 2 0
Significant Ipsilateral Arm Circumference >2% only 11 6 5
Dilated Chest Wall Veins and Significant Ipsilateral Arm Circ 3 2 1
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